Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

AGC Inc.. (3/17/20). "Press Release: AGC Decides to Launch Voluntary Tender Offer for Shares of MolMed".

Organisations Organisation AGC Inc. (JP)
  Group Asahi Glass (AGC) (Group)
  Organisation 2 MolMed S.p.A. (MLMD.MI)
  Group Asahi Glass (AGC) (Group)
Products Product contract manufacturing (biologicals)
  Product 2 cell therapy manufacturing/processing technology
Index term Index term MolMed–Asahi Glass: investment, 202003– cash tender offer €240m for 463.5m shares at €0.518/share by AGC Inc ANNOUNCED
     


AGC Inc., (Headquarters: Tokyo; President & CEO: Takuya Shimamura) has decided to launch a voluntary tender offer (“VTO”) to acquire all ordinary shares of Molecular Medicine S.p.A. (“Molmed”) a company with shares listed on the Italian Stock Exchange (Milan) pursuant to article 102, first paragraph, of the Italy Legislative Decree No. 58 of 24 February 1998 and related regulations. Molmed is a clinical stage biotechnology company focused on research, development, manufacturing and clinical validation of gene & cell therapies, and offers GMP services for the development and manufacturing of gene & cell therapies for third parties and/or in partnership at its authorized facilities (“CDMO Services”*1).

The VTO aims to obtain all of the issued shares of Molmed (463,450,672) at 0.518 Euros/share, amounting to 240 Million Euros if all of the shares are successfully acquired, and the subsequent delisting of the Issuer from the Italian Stock Exchange. This VTO is subject to certain conditions (e.g. the acceptances of the VTO of a number of shares representing not lower than 66.7% of the entire share capital), and is more fully described in the notice to the market issued in accordance with Italian law. Further details of the VTO will be contained in the offer document which will be published in the next few weeks.

This VTO is backed by Molmed’s largest shareholder, Fininvest S.p.A. (holding 23.13% of the shares of Molmed) which has irrevocably undertaken to bring all of its Molmed shares in the VTO, and we expect endorsement from Molmed management as well.

Gene & cell therapy is an innovative therapeutic method, that aim to treat diseases that do not have adequate treatments to date. Approximately 1000 clinical trials are underway worldwide, and the market is expected to grow at a rapid rate. Molmed has strength especially in vectors and cells manufacturing backed by its robust production platform, also providing third party GMP manufacturing services of engineered cells and viral vectors for various companies from large biopharmaceuticals to biotech companies.

Under its AGC plus management policy, the AGC Group has made a commitment to position its life-sciences related business, including the biopharmaceutical CDMO business, as one of its strategic initiatives, aiming at sales above the 100-billion-yen range by 2025. To date, AGC has actively invested in its small molecule pharmaceutical CDMO business and its biopharmaceutical CDMO business, and has established a stable presence in the industry. Through the acquisition of Molmed, AGC will enter into the innovative gene & cell therapy field to expand its CDMO offering to the area where there is a strong imbalance between demand and supply of specific skills and production capacity worldwide, and to better serve the pharmaceutical companies, its patients and society.


Notes:

*1) CDMO: Contract Development & Manufacturing Organization


REFERENCE

> Information on Molmed

Established 1996
Located Milan, Italy
Number of employees App. 220
Revenue 36.3 Million Euros (2019)
Business Arena Gene & Cell therapy Discovery, R&D, Manufacturing, Clinical Validation, Third Party GMP Services.
Issued shares 463,450,672
Website https://www.molmed.com/en/node/1


> Where Molmed fits into AGC’s Business



MEDIA INQUIRIES

Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations Division
AGC Inc.
Contact: Yuki Kitano
TEL: +81-3-3218-5603
E-mail: info-pr@agc.com

   
Record changed: 2023-06-05

Advertisement

Picture Berlin Partner Voices Uirá Souto Melo Lucid Genomics 650x200px

More documents for Asahi Glass (AGC) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px




» top